Moving Towards Safer Prescription Drug Dosing
Respiratory Orphan Drug Strategy
Developing New Prescription Cough Medicines
Partnering and Licensing to Unlock Value
Alitair is dedicated to collaborating with strategic partners to develop therapies to advance unmet medical need
We are actively seeking innovative partnerships to collaborate on developing and commercializing new therapies based on Alitair’s unique IP that will fulfill unmet needs in the respiratory space as well as overdose reduction (ODR) for opioid and other prescription drug categories.
We look to build long-term relationships with organizations who want to partner with Alitair on this important endeavor to serve patients and providers while building value for all partner stakeholders.